Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?
The treatment of hormone receptor-positive, HER2-negative breast cancer has become increasingly individualized, thanks to the development of genomic testing. Gene expression assays provide clinicians and patients with both prognostic and predictive information regarding breast cancer recurrence risk...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publishing
2022-03-01
|
| Col·lecció: | Therapeutic Advances in Medical Oncology |
| Accés en línia: | https://doi.org/10.1177/17588359221084769 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|